Vatalanib Dihydrochloride (CAS: 212141-51-0) is a small molecule drug that has been developed for the treatment of cancer. It is a potent and selective inhibitor of vascular endothelial growth factor receptor (VEGFR). The chemical name for Vatalanib Dihydrochloride is N-(4-chloroanilino)-6,7-dimethoxyquinazoline-2,4-diamine dihydrochloride. Its molecular formula is C20H22ClN5O2.2HCl, and its formula weight is 451.79 g/mol.
Top Ten Keywords from Google:
Synonyms of Vatalanib Dihydrochloride include PTK787/ZK222584, CGP79787B, and N-(4-Chloroanilino)-6,7-dimethoxyquinazoline-2,4-diamine bis-HCl.
Health Benefits of Vatalanib Dihydrochloride:
Vatalanib Dihydrochloride is a potent and selective inhibitor of VEGFR-1, -2, and -3. These receptors play a critical role in the development and maintenance of blood vessels, which are essential for tumor growth and metastasis. By inhibiting VEGFR, Vatalanib Dihydrochloride blocks the formation of new blood vessels, thereby limiting the supply of nutrients and oxygen to the tumor. This leads to decreased tumor growth and increased apoptosis.
Potential Effects of Vatalanib Dihydrochloride:
In preclinical studies, Vatalanib Dihydrochloride has demonstrated potent anti-tumor activity against a variety of different cancer cell lines, including breast cancer, prostate cancer, and pancreatic cancer. In addition, it has been shown to be effective in both in vitro and in vivo models of cancer, indicating that it may have therapeutic potential in human patients.
Product Mechanism:
Vatalanib Dihydrochloride works by specifically targeting and inhibiting the activity of VEGFR. This protein plays a crucial role in promoting angiogenesis, the process by which new blood vessels are formed. By inhibiting VEGFR, Vatalanib Dihydrochloride disrupts the signaling pathways that are essential for cancer cell proliferation and survival. This leads to decreased tumor growth and increased apoptosis.
Safety of Vatalanib Dihydrochloride:
Like all drugs, Vatalanib Dihydrochloride can have side effects. However, the safety profile of Vatalanib Dihydrochloride appears to be favorable based on data from preclinical studies. In these studies, rats were given high doses of Vatalanib Dihydrochloride for extended periods of time without experiencing significant toxicity or adverse events. Further studies are needed to determine the long-term safety and efficacy of Vatalanib Dihydrochloride in human patients.
Side Effects of Vatalanib Dihydrochloride:
The most common side effects of Vatalanib Dihydrochloride are fatigue, nausea, vomiting, and diarrhea. In addition, some patients may experience skin rash, itching, or dryness. These side effects are generally mild to moderate in severity and can usually be managed with supportive care. Rarely, more serious side effects may occur, such as liver toxicity, cardiac toxicity, or interstitial lung disease. If you experience any of these symptoms while taking Vatalanib Dihydrochloride, you should contact your doctor immediately.
Dosing Information:
The optimal dose of Vatalanib Dihydrochloride for human patients has not yet been established. Clinical trials are currently underway to evaluate the safety and efficacy of Vatalanib Dihydrochloride in patients with advanced solid tumors. As with all medications, it is important to follow your doctor's instructions regarding dosing and administration of Vatalanib Dihydrochloride.
Conclusion:
Vatalanib Dihydrochloride is a promising new small molecule drug that shows potential for the treatment of various types of cancer. Its mechanism of action, which involves inhibition of VEGFR, makes it a promising candidate for molecular targeted therapy. While more research is needed to establish its safety and efficacy in human patients, preclinical studies suggest that Vatalanib Dihydrochloride may have significant anti-tumor activity and could ultimately offer new hope for patients with cancer.
